Research Proves Superiority of 3D Bioprinted Human Liver Tissues in Assessing Drug-Induced Toxicity

Organovo Holdings, Inc., a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, today announced a publication in the scientific journal, PLOS One, which demonstrates the superiority of Organovo’s 3D bioprinted human liver tissues to effectively model drug-induced liver injury and distinguish between highly-related compounds with different toxicity profiles.  Continue reading “Research Proves Superiority of 3D Bioprinted Human Liver Tissues in Assessing Drug-Induced Toxicity”

Organovo Patents Methodology for Producing Kidney Cells from Induced Pluripotent Stem Cells

UniQuest, the main technology transfer and commercialisation company of The University of Queensland (UQ), has signed an exclusive worldwide licensing agreement with Organovo Holdings, Inc. (NYSE MKT:ONVO), a three-dimensional biology company focused on delivering scientific and medical breakthroughs using its 3D bioprinting technology, to patent applications relating to methodology for producing kidney cells from induced pluripotent stem cells (iPSCs).

Professor Melissa Little and her team at UQ’s Institute for Molecular Bioscience developed a method of growing kidney tissue from iPSCs for potential use in drug screening, disease modelling and cell therapy. Continue reading “Organovo Patents Methodology for Producing Kidney Cells from Induced Pluripotent Stem Cells”

Organovo and the implementation of 3D printers in BioTechnology

Scientists, scientifically curious investors and Sci-Fi fanatics keep their eyes wide open on Organovo, waiting patiently for the next breakthrough of the company. Organovo developed the first commercial 3D bio-printing platform, and in 2013 the company presented data describing key features of a 3D human liver model, which is in development since then. Continue reading “Organovo and the implementation of 3D printers in BioTechnology”

Organovo Announces Collaboration with National Institutes of Health

Organovo announced today that they are joining together with two institutes from the National Institutes of Health (NIH) to help scientists develop more reliable tools for bringing safer, more effective treatments to patients on a faster timeline. Organovo is collaborating with the National Center for Advancing Translational Sciences (NCATS) and the National Eye Institute (NEI) to develop better and more clinically predictive tissue models using Organovo’s NovoGen MMX Bioprinter®. Organovo will collaborate with NCATS and NEI in using the NovoGen Bioprinting platform to create three-dimensional, architecturally correct, functional living tissues. Continue reading “Organovo Announces Collaboration with National Institutes of Health”